Genomma Lab Internacional SAB de CV Class B · BMV:LAB/B
Genomma Lab Internacional SAB de CV Class B — Investor Presentation (February 2024)
100 slides from Genomma Lab Internacional SAB de CV Class B's investor presentation, February 2024
Slide 1: Genomma Lab Internacional
Genomma Lab.°® Internacional
Slide 2: Investor Relations Corporate Presentation
INVESTOR RELATIONS CORPORATE PRESENTATION
Slide 3: Safe Harbor Disclosure
Safe Harbor Disclosure This presentation may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements
Slide 4: Content
1 Who We Are: Our Footprint 2 4-year Profit & Growth Strategy Content 3 Unleashing Shareholder Value 4 Financial Review February 2024 4
Slide 5: New High-Growth Strategy
* New High-Growth Strategy • “The ideal Partner for • Leading Latin America and the Pharmaceutical U.S. Hispanic Market” and Personal • Europe : United Pharmaceuticals Care Company • U.S. : Edgewell • Japan : Rohto • Israel : Oramed • Assessing selected high-ROIC • Consistent base growth potential p
Slide 6: Footprint: Latin America
Footprint : Latin America CHALLENGES OPPORTUNITIES • General economy • Population + 663 million (2x USA) stagnation • GDP per capita 0.2 x USA • Political inestability • Total GDP = 0.4x USA • Employment & MAPA • Median Age : 31 years Livelihood crisis • Inequality translates into ENMEDIO different
Slide 7: Genomma's Solid Base Business
Genomma’s Solid Base Business Single Digit Growth 3 out of 14 categories Double Digit Infant Formula Growth 50% of all Categories rowth impacted by Palm Oil Contingency despite macroeconomic and supply chain headwinds Anti-acne, Cosmetics & Skin Care categories impacted by lockdowns Net sales growth
Slide 8: Genomma Lab Internacional: Base Business
Genomma Lab Internacional : Base Business • Genomma develops, manufactures and markets a broad range of premium branded products, many of which are leaders in their categories SEGMENT MEGA-BRANDS GEOGRAPHY US PC OTC 10% Mexico 45% 55% LatAm 41% 49% February 2024 8
Slide 9: Over The Counter Products: 55% of Total Sales
Over The Counter Products (OTC): 55% Of Total Sales* Pain Relief Cough & Cold Gastro & Anti- Hemorrhoids Anti-mycotics & Isotonic beverages Anti-Flu Sexual Health *As of December, 2023 February 2024 9
Slide 10: Personal Care Products: 45% of Total Sales
Personal Care Products (PC): 45% Of Total Sales* Specialized Hair Care Skin Care Beauty Care *As of December, 2023 Shampoo Anti-Acne & Cosmetics 10
Slide 11: New Categories
New Categories: Antibacterial Male Care & Grooming Infant Nutrition February 2024 11
Slide 12: International Business Model
International Business Model US dollar: Guatemala 9.9% Honduras El Salvador Other currencies: USA Belize Costa Rica INTERNATIONAL 23.2 41.3% Panama Nicaragua 1. Brazilian Real MEXICO 51.2 2. 3. Colombian Peso Chilean Peso CARICAM 4. Peruvian Sol 5. Argentine Peso Colombia MEXICO 6. 7. Uruguayan Peso
Slide 13: Content
1 Who We Are: Our Footprint 2 4-year Profit & Growth Strategy Content 3 Unleashing Shareholder Value 4 Financial Review February 2024 16
Slide 14: Evolution of Growth Strategy
Evolution of Growth Strategy 4-year trend : consistent Sales and Profit growth MM PS MM PS Net Revenues 3800 EBITDA INITIATIVES TO FURTHER 18000 CAGR CAGR IMPROVE PROFITABILITY 16000 9.7% 3300 10.5% • Manufacturing Plant and 14000 2800 Supply Chain synergies 12000 2300 • AI-based media investment 10
Slide 15: Growth Strategic Framework 2025
Growth Strategic Framework → 2025 Product Innovation Superior Best-In-Class Brand Value Go-To-Market & e-Commerce Our Sustainability Commitment Strategic World-Class Partnerships & Supply Chain Technology Winning Culture & Organization February 2024 19
Slide 16: Product Innovation
Product Innovation Recycled Royal Jelly Shampoo Healthy Hair, Healthy Planet Eco-friendly Recycled Conscious communication 100% 100% recycled sustainable and recyclable packaging PETE bottle Recycling meeting points High quality ingredients February 2024 20
Slide 17: Product Innovation
Product Innovation Masstige Affordable Luxury Hi-quality Performance February 2024 21
Slide 18: New High (Inorganic) Growth Strategy
New High (Inorganic) Growth Strategy M&A • Current environment : high valuations due to global apetite in OTC and PC brands, and low interest rates PARTNERSHIPS • Innovative products and services High ROIC -> • Extensive R&D capabilities Shareholder • Low capital investments value creation • Leverag
Slide 19: The ideal Partner for Latin America and the U.S. Hispanic Market
“The ideal Partner for Latin America and the U.S.Hispanic Market” Genomma Lab Internacional February 2024 23
Slide 20: Strategic Alliances
Strategic Alliances New category with growth potential for Mexico & LatAm Manufactured by Edgewell PC (Strategic Partnership) Market Value opportunity of >100mm USD February 2024 24
Slide 21: Strategic Alliances
Strategic Alliances Manufactured by UP International (Strategic Partnership) Exclusivity in Mexico and Latin America ex. Brazil Market Value opportunity of >80mm USD February 2024 25
Slide 22: Exploring expansion to other territories
Exploring expansion to other territories • Developing a franchise business to expand the presence of power brands in other territories, partnering with strong local players overseas • Low cost manufacturing, sustainable products • Full marketing/advertising and Point-of-Sale material • Cicatricure,
Slide 23: Superior Brand Communication
Superior Brand Communication SOCIAL RESPONSIBILITY Click on images to watch the latest product communication February 2024 27
Slide 24: Proprietary Process to Win the Consumer Experience
Always-on Analytics and Precision Marketing Proprietary Process to Win the Consumer Experience Always-on Analytics and Precision Marketing Understanding Online Market Design Experts Effective Research with Across all of Consumers in communication media Choices Thousands of E-Commerce vehicles platfo
Slide 25: The Largest Content Studio in the World of CPGs and Pharma
The largest Content Studio (25 years) in the world of CPGs and Pharma Companies, now including Digital Content • 25 years developing the largest multi-media content in Latin America • > 2.1 PetaBytes of media content (Over 2,140,000,000 GB of photos, videos, animation & digital content produced in-h
Slide 26: Best in Class Go-to-Market
From the Bottom-of-the-Pyramid to the top Best in Cass Go-to-Market Multi- Channel Traditional Channel Superior POS visibility • +308,000 • Modern Trade Points of Sale • Pharma Wholesalers • Pharma Chain • E-Commerce (B2C) • Amazon & other e-Retailers • Direct Sales Distribution (DSD) • Independent
Slide 27: Corporate Culture & Organization
Corporate Culture & Organization Genomma Way Breaking Down Barriers • GenBook, new corporate How are we doing it? philosophy • Upskilling • Competitive Compensation • Career Development • Connected Organization Equal opportunity February 2024 31
Slide 28: 2025 Sustainability Strategy
2025 Sustainability Strategy Click here to read our 2025 Sustainability Strategy +10 Years Being Recognized As One Of The Leading Companies In ESG Practices. February 2024 32
Slide 29: MSCI ESG Rating Upgrade
MSCI ESG Rating Upgrade Improved three notches in a 4 year period February 2024
Slide 30: Capital Allocation, Ratings & Long-term Financing
Capital Allocation, Ratings & Long-term Financing • CASH DIVIDEND • SHARE BUY-BUCKS • OPTIMIZE FINANCIAL LEVERAGE • STRATEGIC PARTNERSHIPS / M&A Short-Term: Short-Term: F1+(mex) HR+1 Long-Term: Long-Term: AA+(mex) HR AA+ Outlook: Outlook: Stable Stable February 2024 34
Slide 31: World-class Manufacturing & Supply Chain
World-class Manufacturing & Supply Chain Enhanced Value Equation Higher Gross Margin US$ 100 MM Superior Product Quality 8 years term Reliable Product Supply loan 1 2 3 February 2024 35
Slide 32: PC Manufacturing Facility Update
PC Manufacturing Facility Update Suerox® Manufacturing Line +8,000,000 bottles produced in June-23 February 2024 36
Slide 33: PC Manufacturing Facility Update
PC Manufacturing Facility Update Isotonic Beverage Line
Slide 34: Central Warehouse, PC and OTC Manufacturing Facility
Central Warehouse, PC and OTC Manufacturing Facility February 2024 38
Slide 35: OTC Manufacturing Facility Update
OTC Manufacturing Facility Update Tube filling equipment for semi- Water chiller system for OTC Plant solid production line Tanks system for liquid OTC production Semi-solid production line State-of-the-art equipment February 2024 39
Slide 36: Content
1 Who We Are: Our Footprint 2 4-year Profit & Growth Strategy Content 3 Unleashing Shareholder Value 4 Financial Review February 2024 40
Slide 37: Genomma Lab Internacional
Genomma Lab Internacional February 2024 41
Slide 38: Genomma Lab Internacional
Genomma Lab Internacional February 2024 42
Slide 39: Genomma Lab Internacional
Genomma Lab Internacional February 2024 43
Slide 40: Genomma Lab Internacional
Genomma Lab Internacional February 2024 44
Slide 41: Genomma Lab Internacional
Genomma Lab Internacional February 2024 45
Slide 42: Genomma Lab Internacional
Genomma Lab Internacional February 2024 46
Slide 43: Genomma Lab Internacional
Genomma Lab Internacional February 2024 47
Slide 44: Tio Nacho net sales and market share
Brasil Colombia Pert Argentina México +2023 growth rate in like for like currency, excluding Argentina 450.4803 onion ee Category size: LDS, 100% sustainably sourced packaging Successful launch of “anti-canas” Introduction of thé 950ml size Leads the natural products industry trend SOM: Nach 92:5;3B
Slide 45: Tio Nacho Anti-canas
j NOC | CAIDA, Tio Nacho “Anti-canas” Formulated with Egyptian Henna Chemical free % of Tio Nacho Q4. 2023 Sales Ecuador (Ceattelanletie 24% Q12024 Q12024 aes Brasil I I yx po 2% | i i "February 202 OOo
Slide 46: Tio Nacho 950ml size introduction
Introduction of the 950 mil size % of Tio Nacho Q4 950 ml 2023 Sales México 21% Chile 12% Peru 8% CA 2.5% Colombia 1% Ecuador % Brasil % Argentina § Q1 2024 Q12024 SHAMPOO TNA ENGROSADOR JALEA REAL + XTRACTO DE ORTIGA © February 2024
Slide 47: Isotonic beverages (Suerox)
Category size: Isotonic Beverages 1.9 Bn USD 2 CATEGORY »Market expansion to Peru, Chile, Argentina, Caricam, USA and Brazil »Chile Market share up 3.0 pts vs YA +42% Net Sales and share of market evolution CAGR +44% (2018-2023) 2019 2020 2021 2022 3023 023 growth tate in like for like currency, exc
Slide 48: Genomma Lab Internacional
Genomma Lab Internacional February 2024
Slide 49: Country Expansion
SUSey< COUNTRY EXPANSION 2022 COUNTRY FOOTPRINT. 2023 PLAN *RAIA DROGASIL,
Slide 50: Groomen net sales and market share
GROOMEN GRCOMEN PS. MILLION "2023 growth rate In like for like currency, excluding Argentina GROOMEN KEY HIGHLIGHTS: » Chile market share gowth of 1.4pp » Mexico market share growth of 0.2pp » Colombia market share growth of O.8pp Net Sales and share of market evolution CAGR + 50% (2020-2023) +36% 1
Slide 51: Analgesics (Tafirol, X Ray)
Category size: Analgesics 2BnUsD 6% {3 Analgesic Brand lalgesic Brand ULL KEY HIGHLIGHTS: » X Ray Andean Region +48% YoY growth » Tafirol Argentina + 83% YoY growth in local currency, but maintaining market share at 35.8% +24% Net Sales and share of market evolution 2,944 CAGR #14% (2018-2023) ' 1 2
Slide 52: Share of market evolution
ol.) #3 Analgesic Brand SOM Evolution 10% 8% 6% 4% 2% 2.4% XRay Colombia 2019 2020 2021 2022 2023 *Source: CLOSE UP February 2024 0%
Slide 53: Genomma Lab Internacional
Genomma Lab Internacional February 2024 57
Slide 54: Cough & Cold
Category size: Cough & Cold 1i8Bnusp ew ‘C&C Brand .) #3 C&C Brand Next Global C&C Brand KEY HIGHLIGHTS: » Succesful execution during winter season with focus on add value segments (gelcaps, antiviral) » Tukol consolidates the 3% place in Cough category un LATAM ®» XL-3 (+2 pts) mainly in add value
Slide 55: Gastro and Hemorrhoids
Category size: SOM: 1.7 Bn USD 4%) Hemorroids in LATAM & Bloating segment KEY HIGHLIGHTS: » Launch of Genoprazol in Mexico as gastro Megabrand (Q4 + 16%) » Relaunch of Kaopectate in Diarrhea segment » Launch of Genoprazol in Argentina and QG5 in Chile +12% Net Sales and share of market evolution CAG
Slide 56: Derma OTC
Category size: Derma OTC 0.3BnUSD 753% +Unesia #1 in foot Care OTC Latam n Argentina and #2 in México KEY HIGHLIGHTS: » Successful execution during summer season (+1.3pp SOM Latam, +6pp SOM Mx) » Relaunch of Silka Spray in Mexico (+5pp SOM) » Launch of Lomecan Caps in Argentina Net Sales and share o
Slide 57: Novamil infant formula
Category size: Novamil 15 Bn Mxn es TO FEED, TO CARE, TO MANAGE A range of superior science based infant formulas to manage different baby’s needs and improve their quality of life... and that of their families! Net Sales and share of market evolution CAGR +76% (2019-2023) If . 363 339 315 Q3 SEGMEN
Slide 58: Skin Care / Derma
Category size: Skin Care / Derma 258nusD , KEY HIGHLIGHTS: » Launch of Cicatricure Anti-Wrinkle Serum, the fastest-growing format in the category » Launch of Cicatricure Porcelana line to compete in the rapidly growing Anti-Spot segment Net Sales and share of market evolution CAGR -6% (2018-2023) 3,
Slide 59: Genomma Lab Internacional
Genomma Lab Internacional February 2024 63
Slide 60: Packaging cost savings initiatives
CAPS: New supplier development, cap re desin based on Perform specs, improving line production efficencies and cost reduction. SLEEVES: Volume leverage and cost reduction based on cost structure. PREFORM: Re negotiation based on cost structure and weight optimization from 30 grams to 26,5 grams. INI
Slide 61: Vertical integration
LITIO Se. NACHO ES enicacta 5 Vertical integration
Slide 62: Raw Materials Negotiations
Raw Materials Negotiations KEY INITIATIVES: RAW MATERIALS, INGREDIENTS AND API’S » NEW SUPPLIER DEVELOPMENT: Focused on tensoactives and fragances » INGREDIENTS SUBSTITUTION: Risk management and Cost optimization » GLOBAL BIDDING: Fragances and API's : (Paracetamol, Naproxeno) » SUEROX INGREDIENTS:
Slide 63: Productivity Examples
Productivity Examples GO-TO-MARKET MXN 207 MM IN 2023 Effective Price & Promotions
Slide 64: Genomma Lab Internacional
Genomma Lab Internacional February 2024
Slide 65: Genomma Lab Internacional
Genomma Lab Internacional February 2024
Slide 66: Genomma Lab Internacional
Genomma Lab Internacional February 2024
Slide 67: Genomma Lab Internacional
Genomma Lab Internacional February 2024 71
Slide 68: Genomma Lab Internacional
Genomma Lab Internacional February 2024 72
Slide 69: Genomma Lab Internacional
Genomma Lab Internacional February 2024 73
Slide 70: Content
1 Who We Are: Our Footprint 2 4-year Profit & Growth Strategy Content 3 Unleashing Shareholder Value 4 Financial Review February 2024 74
Slide 71: Financial Highlights
4 Financial Highlights February 2024 75
Slide 72: Overall Results
023 OVERALL RESULTS TOP LINE - LIKE FOR LIKE TOP LINE - GLOBAL (WO/ARG) [ 10% P LINE - GLOBAL (W/ARG) % OF SALES GROWING SHARE % OF SALES GROWING AHEAD OF INFLATION 7% € % e -21% € 1% @ +50 bos YOY 15% © 83 Days @ -17 Days VS YA MXN 2.2 Bn @ + 338MM vs YA 3% e 0% © ebruary 2024
Slide 73: 18-year Evolution of Interest Rate Differential (MX vs USA)
18-year Evolution of Interest Rate differential (MX vs USA) Interest Rate Differential +6 months 8.0 1 month 1 month 7.0 6.0 5.0 4.0 3.0 2.0 1.0 - 01/01/2005 01/01/2010 01/01/2015 01/01/2020 SEXENIO 2006-12 SEXENIO 2012-18 SEXENIO 2018-
Slide 74: USD/ARS Exchange Rate Convergence: Official vs Blue
USD/ARS - Exchange rate convergence: Official vs Blue rate 1000 IFRS 800 856 Hyperinflationary Accounting (IAS 29) 600 Currency 400 Translation (IAS 21) 239 Treatment of inflation in IFRS & US GAAP is different 200 may/2023 jun/2023 jul/2023 ago/2023 sep/2023 oct/2023 nov/2023 dic/2023 Blue Official
Slide 75: Statement of Comprehensive Income
Statement of Comprehensive Income FOURTH QUARTER ACCUMULATED Thousands of Mexican pesos 2023 % Sales 2022* % Sales 2023 % Sales 2022* % Sales Net Sales 3,524,736 100.0% 4,132,230 100.0% 16,466,709 100.0% 16,819,912 100.0% Cost of goods sold 1,412,417 40.1% 1,780,601 43.1% 6,383,911 38.8% 6,656,365 3
Slide 76: FY-2023 Income Statement Excl. IAS 29
FY-2023 Income Statement Excl. IAS 29 Reported IAS 29 (2023) IAS 29 (2022) Excl. IAS 29 Inflation Convertion Inflation Convertion FY 2023 2022 Var% Effect Effect Effect Effect 2023 2022 Var% Sales 16,467 16,820 -2.1% 1,280 - 2,224 1,163 - 1,203 17,411 16,860 3.3% EBITDA 3,454 3,453 0.0% 416 - 893 34
Slide 77: Consolidated Financial Position
Consolidated Financial Position As of As of Thousands of Mexican pesos December 31, September 30, 2023 2022 2023 ASSETS Current assets Cash and equivalents and restricted fund 1,670,784 1,503,871 1,763,956 Clients – Net 3,776,838 4,270,528 4,304,510 Recoverable Taxes 1,560,626 1,625,167 1,651,415 Ot
Slide 78: Consolidated Financial Position
Consolidated Financial Position As of As of Thousands of Mexican pesos December 31, September 30, 2023 2022 2023 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities Short-term debt and Current portion of long-term debt 1,946,571 4,826,146 2,247,559 Suppliers 1,842,118 1,790,380 1,990,300 Other
Slide 79: Working Capital Evolution
Working Capital Evolution 205 162 153 154 158 155 139 144 138 145 136 109 100 97 95 82 83 (…) Q1'12 Q2'12 Q3'12 Q4'12 Q1'13 Q2'13 Q3'13 Q4'13 Q1'14 Q2'14 Q3'14 Q4'18 Q4'19 Q4'20 Q4'21 Q4'22 Q4'23 February 2024
Slide 80: Net Debt Evolution
Net Debt Evolution (Millions of MXN) 4,874 4,521 • Net Debt / EBITDA of 1.31x • Net Debt reduction of Ps. 352 million 2022 2023 February 2024
Slide 81: LABB Share Buyback
LABB Share buyback Million shares 35 30.1 30 28 million 25 shares were cancelled on 20 April, 2023 15 10 6.5 5 4.5 2.5 2.8 0 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 February 2024
Slide 82: Cash Dividend Payments
Cash Dividend Payments • 200 million on June 7th • 200 million on September 29th • 200 million on Dec 27th • The Company aims to continue paying dividends on a Quarterly basis February 2024
Slide 83: Canceling Shares
Canceling Shares • 28 million shares cancelled in April 28, 2023 • New total number of shares outstanding 1,020,000,000 • Please update EPS calculation February 2024 87
Slide 84: Annexes
Genomma Lab.° Internacional February 2024 88
Slide 85: Economies of Scale and Scope Driving Higher Gross Margins
Economies Of Scale And Scope Driving Higher Gross Margins Opportunity Outsourcing Producing areas Direct control in all Buying finished Raw Materials products COGS and components Fragmented raw Packaging material Economies of scale procurement Low scale, labor State-of-the-art fully Labor Cost inten
Slide 86: Economies of Scale and Scope Driving Higher Gross Margins
Economies Of Scale And Scope Driving Higher Gross Margins Opportunity Outsourcing Producing areas Higher COGS due to Eliminate co- Suppliers co-packers profit packers profit margin margin Suppliers scattered Integration of throughout the suppliers to country industrial park Logistics Leverage freigh
Slide 87: OTC Market Share By Country
OTC Market Share By Country Top Two Countries Growth Potential Leadership CAM (1) ECUADOR position position position 4th. 4th. 3rd. MEXICO PLACE CHILE > 70% share PERÚ position in the Region position 5th. 6th. position ARGENTINA 1st. COLOMBIA PLACE position 7th. > 30% share Source: IMS Health. Ranki
Slide 88: Profitability Through COGs Reduction
Profitability Through COGs Reduction 38 39 Acquired in 2012 32 34 from Sidus Market 25.4 Share in 24.2 23. 21 21. units (%) 20.3 Competitor ‘13 ‘14 ‘15 ‘16 ‘17 ’18 51 33.91 25.39 Net Sales 20.69 in USD 9.87 13.67 million Portfolio of products ‘13 ‘14 ‘15 ‘16 ’17 ’18 Source: Cid Latina – N02B + M01A.
Slide 89: Industrial Complex EDGE Certification
Industrial Complex– EDGE Certification GENOMMA LAB ACHIEVES WORLD BANK / IFC’s EDGE CERTIFICATION EDGE ISA GREEN BUILDINGSTANDARD AND A GLOBAL CERTIFICATION SYSTEM FIRST PHARMACEUTICAL PLANT IN THE WESTERN HEMISPHERE TO MEET STANDARDS February 2024 93
Slide 90: Industrial Complex EDGE Certification
Industrial Complex– EDGE Certification Plant design enables: PERSONAL CARE PLANT SAVINGS: - 31% in energy - 52% in water - 41% in embodied energy - 87 tons of CO2 PHARMA PLANT SAVINGS: - 45% in energy - 37% in water - 42% in embodied energy - 33 tons of CO2 DISTRIBUTION CENTER SAVINGS: - 26% in ener
Slide 91: OTC Manufacturing Plant Permits Update
OTC Manufacturing Plant Permits Update Granted INTERNATIONAL GMPs Pending Approval Not submitted MEXICO GMP SANITARY LICENSE Solid Semi-Solid Oral Liquid Topical Liquid Coating February 2024
Slide 92: IFC Multi-currency Long-term Loan
IFC and Genomma Lab Multi-currency Long-term Loan • IFC’s first multi-currency investment in the pharmaceutical industry anywhere in the world US$60 million loan: • CHILEAN PESOS • PERUVIAN SOLES • US DOLLARS • MEXICAN PESOS • COLOMBIAN PESOS February 2024 96
Slide 93: Enhancing our Megabrand potential
Enhancing our Megabrand potential Example of Analgesics category February 2024 97
Slide 94: M&A Transactions in Consumer Health Categories
M&A Transactions in Consumer Health Categories CHC MAJOR ACQUISITION MULTIPLES EV / Sales Multiple 9.0 BMS LatAm to Reckitt Paras to Reckitt 8.2 Merck CC to Bayer Adams RT to 6.9 Insight to Prestige 6.5 Swisse to Mead Matrixx to GSK brands Reckitt Church & to Pharma Biostime Johnson Dwight Fertin SG
Slide 95: OTC Pharma EV / LTM EBITDA Transaction Multiples
OTC Pharma EV / LTM EBITDA Transaction Multiples Average 16.3 x Source: Credit Suisse February 2024 99
Slide 96: Dynamism in M&A Pharma
Dynamism in M&A Pharma February 2024 100
Slide 97: Personal Care and Skin Care Price/Sales Transaction Multiples
PERSONAL CARE Price/Sales Transaction Multiples Source: Credit Suisse SKIN CARE Price/Sales Transaction Multiples Source: Credit Suisse February 2024 101
Slide 98: Comparables in the Beverage Industry
Comparables in the Beverage Industry BEVERAGES EV/Sales Transaction Multiple February 2024 102
Slide 99: M&A Dynamism in the Beverage Industry
M&A Dynamism in the Beverage Industry Focused on high growth / high margin brands February 2024 103
Slide 100: Genomma Lab Internacional
Genomma Lab Internacional February 2024 104
Genomma Lab Internacional — Investor Presentation (February 2024) on 6ix